Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
The European Medicines Agency's CHMP has issued a positive opinion recommending Eli Lilly's Jaypirca for the treatment of chronic lymphocytic leukemia.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Jaypirca, known as pirtobrutinib, for adult patients diagnosed with chronic lymphocytic leukemia (CLL). This recommendation covers the use of the drug across all lines of therapy.
Coverage from the European Medicines Agency, GuruFocus, and Yahoo Finance highlights the committee's decision following their June 22-25 meeting. The final decision now rests with the European Commission.
Coverage does not yet specify a timeline for the final marketing authorization.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 37m ago.
Quick answers
What is Jaypirca?
Jaypirca, or pirtobrutinib, is a medicinal product recommended for the treatment of adult patients with chronic lymphocytic leukemia.
Who recommended the approval?
The Committee for Medicinal Products for Human Use (CHMP) issued the positive opinion during its June 22-25, 2026 meeting.
What is the next step for the drug?
The marketing authorization application has been submitted to the European Commission for final consideration.
Coverage (7)
- Matthew Davids' Comments on the New Phase 3 Results From the BRUIN CLL-322 Trial - Dana-Farber Oncodaily · 7h ago
- Eli Lilly (LLY) Gains EMA Support for Cancer and Diabetes Treatm GuruFocus · 7h ago
- Eli Lilly (LLY) Receives Positive EMA Opinion for Jaypirca Treat GuruFocus · 7h ago
- Dr Ahn: Exploring Treatment-Free Remissions With Pirtobrutinib in CLL Targeted Oncology · 7h ago
- U.S. Stocks Move | Eli Lilly and Co (LLY.US) Rises Over 4% as Jaypirca Marketing Authorization Application Submitted to European Commission 富途牛牛 · 7h ago
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy Yahoo Finance · 7h ago
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026 European Medicines Agency (EMA) · 7h ago
Topics
Related trends
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
New clinical data on oral GLP-1 medications is fueling discussions about the future of obesity management and the potential market impact for Eli Lilly.
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
Gene therapy pioneer Sangamo Therapeutics files for bankruptcy, with Lilly and Astellas racing to acquire its assets
Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
Public scrutiny intensifies over the identity of an anonymous 79-year-old patient granted compassionate access to Eli Lilly’s experimental obesity drug, retatrutide.